GRAI-MATTER-LABS
GrAI Matter Labs (GML), a pioneer of brain-inspired ultra-low latency computing solutions, and FRAMOS, a leading global imaging provider, will unite at VISION 2021 to create Life-Ready AI for Industrial Vision Platforms. This project is based on FRAMOS’s D435e Industrial Depth Camera and GML's GrAI VIP (Vision Inference Processor) and was formed to advance vision application development in robotics, automation, IoT-connected manufacturing, and more.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005462/en/
The Life-Ready AI for Industrial Vision Platforms will be built on GML's pioneering development of brain-inspired computing techniques for enhanced efficiencies that leverages FRAMOS’s state of the art stereo depth sensing technology for industrial environments through their D435e stereo depth camera. The platform offers full bodied IP66 rated cameras, or board level modules for easy and flexible integration into industrial designs, both with M12 ethernet and M8 power connectors, and are enabled with ultra low latency AI processing for applications such as orientation and tracking for robots; navigation of autonomous transport systems (AGVs); among some of the many possibilities.
GML and FRAMOS will showcase the integration of the Life-Ready AI platform and D435e Industrial Depth Camera at the Vision 2021 in Stuttgart, Germany, taking place over three days starting October 5th .
“We are proud to be working with FRAMOS to couple GML's "Life-Ready AI" chips, state-of-the-art brain-inspired computing architecture, and FRAMOS' robust D400e depth camera series, to enable many types of new low latency applications in industrial manufacturing that will allow us to bring AI processing closer to where data is generated. This collaboration enables us to realize the full potential of end-point AI, allowing for actionable insights into manufacturing operations to improve productivity and lower costs,” said Christian Verbrugge, GML Europe - Senior Director Business Development.
Ferdinand Reitze, FRAMOS Product Manager 3D, is delighted about the integration, saying: “GML successfully reduced the footprint of AI inference at the edge, while achieving best results, speed and low latency. Together with our D400e series, the Life-Ready AI chips will enable new ways to resolve todays and tomorrows challenges in robotics and automation for our customers.”
About GrAI Matter Labs
At GrAI Matter Labs we are in the business of Life-Ready AI. Artificial Intelligence as close to natural as it gets. AI that feels alive. We deliver brain-inspired chips that behave like humans. AI that makes machines act and react in real-time. AI that optimizes energy and maximizes efficiency, saving time, money, and vital natural resources. GML is led by a team of visionary and seasoned engineers and is backed by leading investors, including iBionext, 360 Capital Partners, 3T Finance, and Celeste Management.
For more information, please visit www.graimatterlabs.ai .
About FRAMOS
FRAMOS® is an imaging expert, trusted advisor, and vision solutions provider. Since 1981 FRAMOS implements the best current and emerging imaging technologies for specific customer requirements and applications. FRAMOS meets these requirements with advanced and proven imaging components from a global network of renowned partners, and proprietary IP.
More than 170 FRAMOS employees world-wide are passionate about the unlimited potential of imaging and help customers achieve the optimum results from every possible scenario. FRAMOS drives and ensures the entire product development journey. This journey starts with the careful selection of imaging components, like image sensors, lenses, through various 3D technologies, to custom development tailored to individual needs and time frames. FRAMOS listens and understands customer challenges. With innovative solutions FRAMOS ensures successful project outcomes and develops long-term customer relations.
For more information, please visit www.framos.com/en/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004005462/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom